Edward Fishman: The Collapse of the Oil Empire?
EPISODE SUMMARY Podcast host Alex Gabuev is joined by Edward Fishman, a senior research scholar at the Center on Global Energy Policy at Columbia University,…
Thought Leader: Edward Fishman
The CBD craze is getting out of hand. The FDA needs to act.
By Scott Gottlieb (Original source Washington Post)
“Cannabidiol — better known as CBD — is everywhere, from small specialty shops to large national retail chains. It can be found in foods, supplements, drugs, oils, creams, pet foods and more, and sellers purport that the compound treats everything from cancer to depression. Analysts say the market could surpass $20 billion by 2024.
But many of the compound’s expansive benefits are fanciful, and in fact, the sale of much of the product is illegal under current law. The Food and Drug Administration must act to make sure commercial interests don’t strip away any legitimate value that the compound might have.
Much CBD is derived from hemp, the commodity that was legalized in the 2018 farm bill. But the law still prohibits putting the chemical in food or pet food, and the FDA has issued repeated warnings and actions on the blooming CBD industry. In fact, there’s only one legally available purified form of CBD: the drug Epidiolex, approved by the FDA in 2018 to treat seizure disorders.”
Click here to see more
Relevant and recent posts
Leana Wen: How long does covid booster protection last?
More evidence highlighting the benefit, and limitations, of covid-19 vaccines. After the Centers for Disease Control and Prevention shifted its coronavirus vaccine guidance from a…
Thought Leader: Leana Wen
Dr. Sanjay Gupta: How Wearable Tech Transforms Health
We’ve come a long way in integrating technology into our daily lives, but could wearable tech actually help you live longer? From detecting heartbeat irregularities to flagging signs of…
Thought Leader: Sanjay Gupta
More with this speaker
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
Scott Gottlieb: China’s edge over U.S. biotech
Thought Leader: Scott Gottlieb